Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

A Pilot Study of the Combination of Entinostat with Capecitabine in Breast Cancer

Research Question:
What are the safety and side effects of combining entinostat, an investigational drug, with capecitabine, a drug commonly used in breast cancer?

Basic Study Information

Purpose:
The purpose of this study is to learn about the safety and side effects of combining entinostat, an investigational drug, with capecitabine, a drug commonly used in breast cancer (BC) - in both participants with metastatic breast cancer (MBC) and then participants with high-risk breast cancer after neo-adjuvant therapy.

Location: University of Rochester Medical Center
Study Reference #: UBRS19042

Lead Researcher (Principal Investigator)

Lead Researcher:  Ajay Dhakal

Study Contact Information

Study Coordinator: Katherine Gerich
Phone: (585) 486-0592
Email: Katherine_Gerich@URMC.Rochester.edu

Additional Study Details

Return to Search